Safety considerations for erythropoietin treatment in patients with cancer

Bibliography

• GROOPMAN JE, ITRI LM: Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl. Cancer Inst. (1999) 91:1616-1634.
   PubMed Web of Science ®Google Scholar
• LUDWIG H, VAN BELLE S, BARRETT-LEE P et al.: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer (2004) 40:2293-2306.
   PubMed Web of Science ®Google Scholar
• KRANTZ SB: Pathogenesis and treatment of the anemia of chronic disease. Am. J. Med. Sci. (1994) 307:353-359.
   PubMed Web of Science ®Google Scholar
• HARRISON LB, SHASHA D, WHITE C et al.: Radiotherapy-associated anemia: the scope of the problem. Oncologist (2000) 5(Suppl. 2):1-7.
   Google Scholar
• LUDWIG H, STRASSER K: Symptomatology of anemia. Semin. Oncol. (2001) 28(Suppl. 8):7-14.
   PubMed Web of Science ®Google Scholar
• PORTENOY RK, ITRI LM: Cancer-related fatigue: guidelines for evaluation and management. Oncologist (1999) 4:1-10.
   PubMedGoogle Scholar
• YELLEN SB, CELLA DF, WEBSTER K et al.: Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J. Pain Symptom Manage. (1997) 13:63-74.
   PubMed Web of Science ®Google Scholar
• CELLA D, ZAGARI MJ, VANDOROS C et al.: Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J. Clin. Oncol. (2003) 21:366-373.
   PubMed Web of Science ®Google Scholar
• CELLA D, ETON DJ, FAIRCLOUGH DL et al.: What is a clinically meaningful change on the Functional Assessment of Cancer Therapy – Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J. Clin. Epidemiology (2002) 55:285-295.
   PubMed Web of Science ®Google Scholar
• CARO JJ, SALAS M, WARD A et al.: Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer (2001) 91:2214-2221.
   PubMed Web of Science ®Google Scholar
• VAUPEL P, THEWS O, HOECKEL M: Treatment resistance of solid tumors: role of hypoxia and anemia. Med. Oncol. (2001) 18:243-259.
   PubMed Web of Science ®Google Scholar
• FEIN DA, LEE WR, HANLON AL et al.: Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J. Clin. Oncol. (1995) 13:2077-2083.
   PubMed Web of Science ®Google Scholar
• LEE WR, BERKEY B, MARCIAL V et al.: Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int. J. Radiat. Oncol. Biol. Phys. (1998) 42:1069-1075.
   PubMed Web of Science ®Google Scholar
• GROGAN M, THOMAS GM, MELAMED I et al.: The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer (1999) 86:1528-1536.
   PubMed Web of Science ®Google Scholar
• VAUPEL P, THEWS O, MAYER A et al.: Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther. Onkol. (2002) 178:727-731.
   PubMed Web of Science ®Google Scholar
• ESTRIN JT, SCHOCKET L, KREGENOW R et al.: A retrospective review of blood transfusions in cancer patients with anemia. Oncologist (1999) 4:318-324.
   PubMedGoogle Scholar
• BARRETT-LEE PJ, BAILEY NP, O’BRIEN ME et al.: Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br. J. Cancer (2000) 82:93-97.
   PubMed Web of Science ®Google Scholar
• BLAJCHMAN MA, VAMVAKAS EC: The continuing risk of transfusion-transmitted infections. N. Engl. J. Med. (2006) 355:1303-1305.
   PubMed Web of Science ®Google Scholar
• STAINSBY D, RUSSELL J, COHEN H, LILLEYMAN J: Reducing adverse events in blood transfusion. Br. J. Haematology (2005) 131:8-12.
   PubMed Web of Science ®Google Scholar
• PIRKER R, WIESENBERGER K, MINAR W: Cancer-related anemia: clinical relevance and treatment strategies. Am. J. Cancer (2005) 4:233-245.
   Google Scholar
• LUDWIG H: Epoetin beta in oncology: examining the current evidence. Future Oncol. (2006) 2:21-38.
   PubMedGoogle Scholar
• ENGERT A: Recombinant human erythropoietin in oncology: current status and further developments. Ann. Oncol. (2005) 16:1584-1595.
   PubMed Web of Science ®Google Scholar
• GLASPY J, BUKOWSKI R, STEINBERG D et al.: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J. Clin. Oncol. (1997) 15:1218-1234.
   PubMed Web of Science ®Google Scholar
• DEMETRI GD, KRIS M, WADE J et al.: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J. Clin. Oncol. (1998) 16:3412-3425.
   PubMed Web of Science ®Google Scholar
• GABRILOVE JL, CLEELAND CS, LIVINGSTON RB et al.: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J. Clin. Oncol. (2001) 19:2875-2882.
   PubMed Web of Science ®Google Scholar
• LITTLEWOOD TJ, BAJETTA E, NORTIER JW et al.: Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. (2001) 19:2865-2874.
   PubMed Web of Science ®Google Scholar
• QUIRT I, ROBESON C, LAU CY et al.: Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J. Clin. Oncol. (2001) 19:4126-4134.
   PubMed Web of Science ®Google Scholar
• CHANG J, COUTURE F, YOUNG S et al.: Once weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J. Clin. Oncol. (2005) 23:2597-2605.
   PubMed Web of Science ®Google Scholar
• OSTERBORG A, BRANDBERG Y, MOLOSTOVA V et al.: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J. Clin. Oncol. (2002) 20:2486-2494.
   PubMed Web of Science ®Google Scholar
• BOOGAERTS M, COIFFIER B, KAINZ C: Impact of epoetin beta on quality of life in patients with malignant disease. Br. J. Cancer (2003) 88:988-995.
   PubMed Web of Science ®Google Scholar
• PIRKER R, LEHNERT M, MINAR W: Once-weekly epoetin beta (30,000IU) in anemic patients with lung cancer receiving chemotherapy. Lung Cancer (2006) (In Press).
   Google Scholar
• PIRKER R, SMITH R: Darbepoetin alfa: potential role in managing anemia in cancer patients. Expert Rev. Anti-Cancer Ther. (2002) 2:377-384.
   PubMedGoogle Scholar
• VANSTEENKISTE J, PIRKER R, MASSUTI B et al.: Double-blind, placebo-controlled, randomized Phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J. Natl. Cancer Inst. (2002) 94:1211-1220.
   PubMed Web of Science ®Google Scholar
• HEDENUS M, ADRIANSSON M, SAN MIGUEL J et al.: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br. J. Haematol. (2003) 122:394-403.
   PubMed Web of Science ®Google Scholar
• SEIDENFELD J, PIPER M, FLAMM C et al.: Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J. Natl. Cancer Inst. (2001) 93:1204-1214.
   PubMed Web of Science ®Google Scholar
• GLASER CM, MILLESI W, KORNEK GV et al.: Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int. J. Radiat. Oncol. Biol. Phys. (2001) 50:705-715.
   PubMed Web of Science ®Google Scholar
• LAVEY RS, DEMPSEY WH: Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. (1993) 27:1147-1152.
   PubMed Web of Science ®Google Scholar
• SWEENEY PJ, NICOLAE D, IGNACIO L et al.: Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial. Br. J. Cancer (1998) 77:1996-2002.
   PubMed Web of Science ®Google Scholar
• RIZZO JD, LICHTIN AE, WOOLF SH et al.: Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J. Clin. Oncol. (2002) 20:4083-4107.
   PubMed Web of Science ®Google Scholar
• CRAWFORD J, CELLA D, CLEELAND CS et al.: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer (2002) 95:888-895.
   PubMed Web of Science ®Google Scholar
• VANSTEENKISTE J, TOMITA D, ROSSI G, PIRKER R: Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline. Support. Care Cancer (2004) 12:253-262.
   PubMed Web of Science ®Google Scholar
• THATCHER N, DE CAMPOS ES, BELL DR et al.: Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br. J. Cancer (1999) 80:396-402.
   PubMed Web of Science ®Google Scholar
• BOKEMEYER C, AAPRO MS, COURDI A et al.: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur. J. Cancer (2004) 40:2201-2216.
   PubMed Web of Science ®Google Scholar
• BOHLIUS JF, LANGENSIEPEN S, SCHWARZER G et al.: Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J. Natl. Cancer Inst. (2005) 97:489-498.
   PubMed Web of Science ®Google Scholar
• BOHLIUS J, WILSON J, SEIDENFELD J et al.: Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J. Natl. Cancer Inst. (2006) 98:708-714.
   PubMed Web of Science ®Google Scholar
• LEYLAND-JONES B; on behalf of the BEST INVESTIGATORS AND STUDY GROUP: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncology (2003) 4:459-460.
   PubMed Web of Science ®Google Scholar
• LEYLAND-JONES B, SEMIGLAZOV V, PAWLICKI M et al.: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanaemic patients with metastatic breast cancer receiving firstline chemotherapy: a survival study. J. Clin. Oncol. (2005) 23:5960-5972.
   PubMed Web of Science ®Google Scholar
• HENKE M, LASZIG R, RÜBE C et al.: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet (2003) 362:1255-1260.
   PubMed Web of Science ®Google Scholar
• ACS G, ACS P, BECKWITH SM et al.: Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. (2001) 61:3561-3565.
   PubMed Web of Science ®Google Scholar
• YASUDA Y, FUJITA Y, MATSUO T et al.: Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis (2003) 24:1021-1029.
   PubMed Web of Science ®Google Scholar